For how we live.
WHO validated Bhutan's elimination of dog-transmitted human rabies, a disease almost always fatal once symptoms appear. The country has recorded zero such deaths since June 2023.
The Vaccine Integrity Project, formed in 2025 amid disruptions to the CDC's immunisation advisory committee, sets out its process for reviewing 2026–2027 respiratory-season vaccines.
JAMA published paired systematic reviews for the coming respiratory season. Both found vaccines reduced hospitalisation across age groups, with no new safety signals, though protection wanes over time.
WHO recorded serogroup W135 disease in pilgrims returning from Saudi Arabia in early 2025. A modelling study estimates high vaccination coverage would cut expected cases by more than 80%.
Gavi is funding a standing mpox vaccine stockpile, coordinated by the same group that manages emergency supplies for cholera, yellow fever and Ebola, to avoid repeating the 2022 access gap.
Ervebo was licensed against Zaire ebolavirus. WHO says it is not known whether it protects against Bundibugyo virus in humans — which is why a trial is running alongside the wider rollout.
Two pragmatic randomised trials and a Medicare nursing home cohort landed in the same week. Together they show real protection against hospitalisation and a durability question nobody has answered.
Comparing US adults vaccinated just before and just after the changeover from the live to the recombinant shingles vaccine, researchers found a 9% lower cardiovascular burden over seven years.
A registry analysis of Abyan Governorate from 2020 to 2024 puts numbers on a vaccine-preventable disease that returned as immunisation coverage fell — with the heaviest toll among children aged 5 to 9.
HHS Secretary Kennedy held the money over Gavi's use of a mercury-based preservative most safety reviews call harmless in trace amounts. Gavi says it was already phasing the ingredient out.
An analysis of a decade of surveillance data shows the system leans heavily on hospitals and misses cases in the community — the weakness that lets measles circulate undetected between outbreaks.
A ruling comes in November. The country has held the status since 2000, and 2026 has already produced more cases than any year in three decades.
The advisory committee that shaped U.S. immunization policy for decades was replaced, then bypassed. In March a judge stayed the result.
Three surveillance networks put 2025/26 effectiveness between 22% and 45% against a drifted H3N2 virus. The figure is a comparison between vaccinated and unvaccinated people who all got tested.
VPM1002 did not show non-inferiority to BCG for preventing tuberculosis infection in a phase 3 trial across sub-Saharan Africa. Far fewer infections occurred than planned, leaving the comparison unresolved.
Two national studies settle the question the trials could not: in England, cancer rates fell 87% among those vaccinated at 12-13; in Sweden, the risk was cut by nearly two-thirds.
Blood samples from a West African vaccine trial show both licensed Ebola vaccines generate antibodies that bind Bundibugyo virus — the species with no vaccine of its own, now causing DRC's largest outbreak on record.
The appeal is moving on an expedited track, with a status report due this month. But CIDRAP's vaccine-policy trackers make a pointed argument: a working committee could exist right now, if HHS chose to seat one.
Years of observational data suggested 4CMenB cut gonorrhea risk by a third or more. A placebo-controlled trial in 654 people at high risk found essentially no effect at all.
CDC data through July 2 puts 2026 at 2,170 confirmed cases, just short of all of 2025's 2,289. Ninety-three percent of this year's cases are linked to active outbreaks.
A New England Journal of Medicine review of the ongoing outbreak lays out what is and isn't known about treating Bundibugyo virus disease — and why Ebola virus countermeasures may offer partial cover.
The committee's founding document now asks for a 'balanced range' of expertise rather than vaccine-specific knowledge, and adds review of non-vaccine alternatives to its mandate.
A Lancet evaluation of the RTS,S introduction in Ghana, Kenya and Malawi reports a 13% drop in mortality among vaccine-eligible children — achieved with third-dose coverage of 71% and fourth-dose uptake under 40%.
Judge Brian Murphy found the government likely broke two federal laws when it bypassed ACIP and replaced its members. The ruling reverts the childhood schedule and cancels this week's ACIP meeting.
WHO updated all three components for the 2026-2027 northern hemisphere season after subclade K dominated globally, and recommended a new candidate vaccine virus for an H9N2 avian strain.
The objection turns on a no-treatment arm. WHO says placebo or no-treatment vaccine trials are acceptable only where no proven intervention exists, and here one does.
A study in patients with VITT maps the trigger to a specific epitope on an adenoviral core protein, and to a single amino acid change that redirects the antibody onto a human platelet protein.
Global oral cholera vaccine supply has roughly doubled since 2022, enough to release 20 million doses for prevention rather than outbreak response. Nearly all of it comes from a single company.
The American Academy of Pediatrics' 2026 schedule covers 18 diseases and carries 12 outside endorsements. The federal schedule signed three weeks earlier lists 11 vaccines for all children.
Eleven vaccines remain recommended for all children. The rest move to risk-based or shared-decision categories, on the strength of a comparison with 20 other countries.
A federal recommendation is load-bearing for insurance coverage, the Vaccines for Children programme, and school requirements. States have started building alternatives to all three.
The 5 December directive tells HHS and the CDC to compare the American childhood schedule with those of other wealthy nations, using a count of diseases as its benchmark.
ACIP replaced a recommendation in place since 1991 with individual decision-making for babies born to mothers who test negative. The CDC has not yet adopted it.
The Bulape outbreak in Kasai Province ended 88 days after it was declared, with a case fatality ratio above 70% and nearly 48,000 people vaccinated.
A TB vaccine financing plan, six target product profiles for children's cancer drugs, and a paediatric research agenda. All three are attempts to specify a product before a market decides to build it.
The committee meets 18-19 September on COVID-19, hepatitis B and MMRV vaccines. RSV was dropped two days before. Adopted recommendations carry insurance and Vaccines for Children consequences.